NunaBio is a privately-owned specialist DNA development company.
We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects.
We work through detail design, integration, and initial testing, repeating this process to optimise the design before verification testing.
Our work is fully documented and a package of data and specifications can be assembled to allow scale up manufacture to start smoothly.
We use enzymatic processes to manufacture DNA.
Not only does this reduce the consumption of reagents, it also eliminates the use of hazardous chemicals and the production of toxic waste associated with other methods.
Our processes support the UK Life Sciences Strategy 2021 aim of escalating biologics development and manufacture to build resilience against future pandemics and we can propel novel therapeutics and diagnostics to clinic, accelerating innovation and improving patients’ lives.
Meet the Team.
Joe Hedley, PhD, MBA.
As Co-Founder and CEO, Joe has over 10 years’ experience in novel DNA based biotechnologies. Joe has developed and delivered successful sales strategies, led new business development and partnerships with SMEs, academia, and multi-nationals. Managed and led high profile (£M) and award-winning product developments with associated quality and regulatory requirements. He has also secured and managed £M10’s in UK and EU grants as well as supporting company investment to a number of SMEs.
Eimer Tuite, PhD.
Eimer is Chief Scientific Officer and Co-Founder of NunaBio. A global authority in molecular electronics, imaging, and DNA-diagnostics, Eimer brings with her a skillset that spans physics, biochemistry, and structural biology.
Andrew Pike, PhD.
Andrew is Chief Technology Officer and Co-Founder of NunaBio. He has over 40 peer-reviewed publications on synthesising functional DNA-based nanomaterials via enzymatic and solid-phase methods. His academic research focuses on the synthesis, structure, and function of DNA.
Colin (BVM&S, CertEP, CertVBM, MRCVS) is NunaBio’s Independent Board Chair bringing a wealth of experience as a business owner and manager together with professional qualifications from Institute of Directors and The University of Law.
Alex Buchan, PhD.
Investment Director NorthStar Ventures
Alex makes and manages investments into a wide range of technology businesses in the health-tech and green-tech sectors, often acting as Board Observer or Investment Director.
Alisa Molotova, PhD.
Investment Manager Martlet Capital
Alisa has worked in deep science and technology and supported strategic innovation projects.
Sandy Primrose, PhD.
Sandy has experience in the development and exploitation of new products and processes in the fields of life sciences, diagnostics, medical devices and biopharmaceuticals including the development of appropriate business strategies and troubleshooting product and process development.
Investment Partner, Ascension Ventures
Chris manages a portfolio of tech and fin-tech companies and has successfully fundraised and exited a number of companies within this space.
Biotech and Health Investor, Pioneer Group
Gemma works at the forefront of venture building and has experience of mentoring pre-spin out and early stage Bio & HealthTech teams.